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Purpose: Age has been evaluated as a prognostic
factor in cervical cancer in both hospital- and
population-based studies. Results regarding the rela-
tion of age and cervical cancer prognosis are conflict-
ing. This study pursued a contemporary assessment of
the association of extreme young age at the time of a
cervical cancer diagnosis on survival.
Methods: Institutional review board approval was
obtained, and retrospective data collection at 2 aca-
demic institutions was performed. Inclusion criteria
involved women ≤35 years diagnosed with cervical
cancer between 1990 and 2012. Data included dem-
ographic and prognostic information pertinent to
survival and progression. Characteristics of very
young (r25 years) and young (425–35 years)
women were compared. Kaplan-Meier estimates, the
log-rank test, and Cox proportional hazards modeling
were used to assess the association of age, tumor
histology, grade, stage, and parametrial involvement
with progression-free survival (PFS) and overall
survival (OS).
Findings: Incident cases (n ¼ 126) of cervical
cancer in patients ≤35 years of age were identified
of which complete clinical information was available
for 114 women. Fifteen percent (17 of 114) werer25Accepted for publication January 7, 2016.
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March 2016years, with the remaining 85% (97 of 114) being 26 to
35 years of age. Race, smoking status, and marital
status were comparable between the 2 groups. Squ-
amous histology dominated overall (77 of 114; 68%)
with adenocarcinoma contributing 25% (30 of 114;
26%) of cases. The majority (96 of 114, 84%) had
either stage 1A (31 of 114, 27%) or 1B (65 of 114,
57%) disease. A log-rank test revealed no evidence to
infer a difference in either PFS or OS among the age
groups (P ¼ 0.511 and P ¼ 0.340). In a univariate
analysis, grade and stage significantly affected OS
(P o 0.0001, P ¼ 0.045), and stage significantly
affected PFS (P o 0.0001). In multivariate modeling,
presence of parametrial involvement and histologic
cancer type significantly affected both PFS (P ¼ 0.002,
P ¼ 0.001) and OS (P ¼ 0.001, P ¼ 0.001).
Implications: Tumor histology, parametrial in-
volvement, and stage continue to be strong prognos-
ticators for PFS and OS. Progression and survival
outcomes are age independent in women with cervical
cancer r35 years of age. Further study of a larger
young cohort may potentially yield different out-
comes. (Clin Ther. 2016;38:459–466) & 2016 Elsevier
HS Journals, Inc. All rights reserved.
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Clinical TherapeuticsINTRODUCTION
Cervical cancer, although largely preventable, is the
most common site of gynecologic malignancy in
women o35 years of age in the United States.
Worldwide, cervical cancer is second only to breast
cancer in cancers that affect women.1 Young patient
age has been posited as a risk factor for more
aggressive cervical cancers. Alternatively, although
no genetic predisposition for cervical cancer has
been accepted, researchers have proposed that there
is a heritable inability to clear human papillomavirus
(HPV) infection because population studies have
found an increased incidence of cervical cancer in
some families. In a Swedish study of 49000 siblings
or half-siblings with cervical cancer or dysplasia, 64%
of cases were attributed to genetics and only 36% to
environmental exposures.2 It seems improbable for
young women to develop advanced disease, given the
classic teaching that the risk of progression from mild
dysplastic changes of the cervix to severe dysplasia,
let alone cancer, is only 1% per year.3 Therefore, the
development of cancer in young women, especially the
very young, has led to the theory that cervical cancer
in the very young must be more aggressive.4 Others
blame changes in sexual behavior with an earlier age
of first intercourse, greater frequency of multiple
partners and HPV infection, and tobacco use for the
observations.5–8 Current estimates put the prevalence
of HPV (all types) at 59% in 20- to 24-year-old
women and 50% in 25- to 29-year-old women.9
Several investigators have examined the relation
between age at diagnosis and prognosis with conflicting
results. In a study by Rutledge et al,10 250 womenr35
years were matched by stage and treatment to older
women. Younger women with advanced stage disease
were noted to have worse overall survival (OS), yet they
survived longer when diagnosed with early-stage dis-
ease. Conversely, Clark et al11 concluded that cervical
cancer behaved more aggressively in their comparison
of 41 womenr35 years old with 96 women agedZ36
years in that there was a higher incidence of nodal
metastases observed in the younger patients despite less-
advanced clinical stage of disease. Paradoxically, they
simultaneously observed that youth conferred better
survival outcomes overall. In other studies, clinical
behavior was age independent, but these studies com-
pared women o35 years with older women.12–14 Our
hypothesis is that cervical cancer in the very young
(women o25 years) is a more aggressive disease.460We sought to evaluate the relation of very young
age to aggressiveness of cancer by comparing the
young with the very young. This is a contemporary
investigation after changes to practice that followed
the 1999 National Cancer Institute alert that all
patients with cervical cancer treated with radiation
should also receive sensitizing cisplatin.
The primary objective of this study was to assess
the effect of age on progression-free survival (PFS) and
OS in women with cervical cancer r35 years of age.
Secondarily, we sought to evaluate the impact of
tumor histology, grade, stage, and parametrial in-
volvement on PFS and OS in this cohort.
METHODS
Retrospective data collection was performed after
approval from the institutional review boards at 2
tertiary academic medical centers (University of Vir-
ginia Health System, Charlottesville, VA; University of
North Carolina, Chapel Hill, NC). Data for patients
with cervical cancer aged r35 years treated between
1990 and 2012 were abstracted.
Chart review included abstraction of demographic
information (age, race, smoking status, and marital
status), disease characteristics (histology, grade, stage,
parametrial involvement), treatment history (surgery,
radiation, chemotherapy, combination), and outcome
data (OS and time to recurrence).
To assess the primary outcome of the effect of age on
PFS and OS, patients were classified according to age at
diagnosis. These age groups were defined as very young
(r25 years old) and young (425–35 years old)
women. PFS was defined as the time from date of
diagnosis to disease progression or death from any
cause. OS was defined as the time from date of
diagnosis to death from any cause. Secondary outcomes
included assessing the effect of tumor histology, grade,
stage, and parametrial involvement on PFS and OS.
Differences in OS and PFS among the age groups
were evaluated with Kaplan-Meier survival estimates
and the log-rank test. Multivariate Cox proportional
hazards modeling was used to perform time-to-event
analysis of OS and PFS, including the predictors
tumor histology, parametrial involvement, and age.
Tumor grade was not stated for 420% of women,
and some subgroups of stage were too small and
observed no events, so these variables were excluded
from our final multivariate model. Significance wasVolume 38 Number 3
Table I. Patient demographic and clinical chara-
cteristics (N ¼ 114).
Characteristic Value
E. Pelkofski et al.determined with a Wald test, and differences were
considered significant for P values (2-sided) r 0.05.
Assumptions of the Cox proportional hazards model
were assessed with graphical methods.Mean age at diagnosis
(range), years
29.7 (17–35)
Race, n (%)
Caucasian 86 (75.4)
Black 15 (13.2)
Hispanic 13 (11.4)
Marital status, n (%)
Single 39 (34.2)
Married 55 (48.2)
Divorced 13 (11.4)
Widowed 1 (0.88)
Unknown 6 (5.3)
Smoking status, n (%)
Current 35 (30.7)
Former 13 (11.4)
Never 62 (54.4)
Unknown 4 (3.5)
Stage at diagnosis, n (%)
1A1 25 (21.9)
1A2 6 (5.3)
1B1 37 (32.5)
1B2 28 (24.5)
IIA1 0
IIA2 2 (1.7)
IIB 10 (8.7)
IIIA 0
IIIB 4 (3.5)
IV 2 (1.7)
Histology, n (%)
Squamous 77 (67.5)
Adenocarcinoma 30 (26.3)
Small cell 5 (4.4%)
Adenosquamous 2 (1.7)
Grade, n (%)
1 18 (15.8)
2 35 (30.7)
3 35 (30.7)
Unknown 26 (22.8)
Parametrial involvement, n (%)
No 94 (82.5)
Yes 15 (13.2)
Unknown 5 (4.4)RESULTS
A total of 126 women with cervical cancer were
identified from the 2 institutions. Complete clinical
information was available for 114 women, and they
comprise the study group. Approximately 15% (17 of
114) were very young, with the remaining 85% (97 of
114) belonging to the young group. Despite a 23-year
searchable study time frame, the oldest case in the
final cohort dated back to 1998. Demographic and
clinical characteristics are summarized in Table I.
The mean age at diagnosis was 29.7 years (median,
30 years; range, 17–35 years). The majority of
patients were Caucasian (75%), 13% were black,
and 11% were Hispanic. Nearly half were married.
Most patients were never-smokers. Of the 114 with
data available, 22% of women were nulliparous, and
parity was Z2 in 63% of the cohort.
Squamous histology dominated overall (68%)
with adenocarcinoma contributing 25% of cases.
Squamous histology was present in 10 of the 17 very
young women (58%) versus 67 of the 97 young
women (69%) with adenocarcinoma being the next
most prevalent (4 of 17, 24% and 26 of 97, 27%,
respectively). There were 5 cases of small cell carci-
noma with 2 occurring in women o25 years of age.
More than 80% of women in both groups had
early-stage disease (stage 1A or 1B). Of the 109
women for whom a description of parametrial disease
extension was available, only 15 had involvement,
and this was unrelated to patient age. Of the 88
patients for whom tumor grade was stated, cancers
were more often grade 2 (35 of 88, 40%) or grade 3
(35 of 88, 40%), with only 20% (18 of 88) being
grade 1.
Associations of age with PFS and OS, as assessed
by Kaplan-Meier estimation, are presented in Figures 1A
and 1B. Neither PFS (log-rank P ¼ 0.511) nor OS
(log-rank P ¼ 0.340) were significantly different by
age group (r25 vs 425 years old).
The entire cohort had a 5-year OS rate of 42.1%
(48 of 114). When analyzed according to disease
distribution, this equated to a rate of 46% for patientsMarch 2016 461
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Figure 1. (A) Kaplan-Meier survival graphs of age versus progression-free survival (P ¼ 0.511). (B) Kaplan-
Meier survival graphs of age versus overall survival (P ¼ 0.340).
Clinical Therapeuticswith localized disease, 25% for patients with region-
alized disease, and 0% for patients with distant
disease. In univariate analyses (Table II), PFS and462OS were evaluated across 5 categories of stage (1A1,
1A2, 1B1, 1B2, and stage II to IV) and 3 levels of
tumor grade (1–3). Higher tumor grade conferred anVolume 38 Number 3
Table II. Univariate analysis of key variables and
clinical outcomes.
Variable
Progression-free
survival
Overall
survival
Stage o0.0001 o0.0001
Grade 0.053 0.0455
Reported as P values.
E. Pelkofski et al.increased risk of recurrence or progression. As stage
increased, recurrence increased, and survival
decreased. Both stage and grade significantly affected
OS (P o 0.0001, P ¼ 0.045), and stage significantly
affected PFS (Po 0.0001). A trend was found toward
grade significantly affecting PFS; however, this
relation did not reach statistical significance (P ¼
0.053).
Cox proportional hazard modeling (Table III) of
variables associated with PFS or OS indicated that
there was no association between age and PFS (hazard
ratio [HR] ¼ 1.07; P ¼ 0.315) or OS (HR ¼ 1.05; P ¼
0.468). Absence of parametrial involvement was
associated both with improved PFS (HR ¼ 8.71; P ¼
0.002) and OS (HR ¼ 7.39; P ¼ 0.001). Approximately
40% of patients with parametrial involvement recurred or
progressed compared with only 10% of patients without
parametrial involvement. Results from the multivariate
model in Table III indicate that both squamous and
adenocarcinoma tumor histology were associated withTable III. Multivariate analysis of key variables and clini
PFS
Variable Hazard ratio
Histology*
Squamous 0.066
Adenocarcinoma 0.035
Parametrial involvement 8.710
Age 1.071
*The reference group is ‘Other’ tumor histology.
†Cumulative P value for all histology types.
March 2016improved PFS and OS. Women with adenocarcinoma
were the least likely to recur or progress (3%) compared
with 14% of women with squamous histology and
57% of women with other histologic types.
CONCLUSIONS
According to estimates, cervical cancer is the most
common gynecologic malignancy in women o35
years old with an incidence of 16.5 per 100,000.15,16
An abnormal Pap smear or cervical biopsy was the
presenting complaint in nearly 60% of women in our
cohort. This finding provides additional support for
the need for continued screening in this young pop-
ulation to the extent set forth by the American College
of Obstetricians and Gynecologists.17 In addition to
screening, efforts at primary prevention via HPV
vaccination should continue. Large clinical trials have
found HPV vaccination to be effective in preventing
cervical disease associated with HPV-16 and HPV-18;
however, immunization is most beneficial in HPV-
naive women.18 Screening remains important because
25% of cancers will not be prevented by earlier
vaccine types that did not immunize against all
HPV types.
For women found to have cervical cancer, our
findings indicate age at diagnosis in and of itself in
women r35 years of age is not associated with a
worse prognosis (Table III). Because there were only
17 patients o25 years of age in the very young
cohort, statistical difference may not have been
noted, but that group did have worse survival rates,
as displayed in Figures 1A and 1B. In addition bothcal outcomes.
OS
P Hazard ratio P
0.001† 0.001†
0.001 0.069 0.0009
0.004 0.022 0.002
0.002 7.395 0.001
0.315 1.05 0.468
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Clinical Therapeuticsgroups fared worse than survival in older women. The
percentage of women survivingZ5 years in this study
according to local and regional disease was 46% and
25%, respectively, compared with historic 5-year
relative survival by stage at diagnosis for women
Z50 years of age of 87% for localized disease and
54% for regional disease.19 This could point to a
different disease pathway in younger women, leading
to a more aggressive disease due to host or other
unknown factors.
Similar to their older counterparts, tumor grade
and histology affected prognosis and specifically PFS
in our cohort. Analogous to patients with cervical
cancer of all ages, squamous histology predominated
in nearly 68% of cases in this study, and 26% of
patients had adenocarcinoma.20 Compared with
historic trends, this rising proportion of invasive
adenocarcinoma especially in younger white women
is consistent with the findings of other researchers.21,22
This may be due to greater recognition and more
awareness of adenocarcinoma and improved detection
of its precursor lesions through better endocervical
sampling techniques.23
It has been reported that adenocarcinoma confers
poorer survival rates than squamous cell carcinoma,
particularly for patients with regional disease.21,24 All
patients in our study with adenocarcinoma had
localized disease, and cases were fairly evenly distrib-
uted among the 2 age groups. Despite the absence of
adenocarcinoma histology in women having regional
and distant disease, we found that histology still
substantially affected OS and that the aggregate
histologic proportions were similar to larger
population-based studies.
More than 2% of patients in this study had small
cell carcinoma. Historically, this rare and aggressive
histology has been observed to occur at a mean
incidence of only 0.06 per 100,000 women; thus, its
substantially higher rate in this series may affect our
findings.25 Nevertheless, although the recent work of
Castanon et al26 in a series that examined 1800 cases
of cervical cancer in women aged 20 to 29 years
between 2007 and 2012 found a low non-squamous,
non-adenocarcinoma, and non-adenosquamous rate
of 2%, the rare histologic subtypes were most com-
monly found in the youngest women in the series,
aged 20 to 24 years, at a rate of nearly 6%.
Furthermore, 20% of the time, these younger women
were diagnosed at a higher stage of disease (stageZ2)464compared with frequencies of 4% and 7% for their
older counterparts (age 25 years and age 26–29 years,
respectively). This trend was similar in our study with
17% of patients aged 20 to 29 years having been
diagnosed at stage Z2.
Nearly 30% of cases in the youngest women
occurred in those r20 years old. This is in contrast
to an analysis of national surveillance data by Bernard
et al27 in which 1% of cervical carcinoma was
diagnosed in this young age range. This discrepancy
may indicate a regional variation in our patient cohort
or may be due to referral bias of younger, higher risk
women to academic medical centers and thus may
limit the generalizability of our findings.
Recent evidence from Japan epidemiologic data
found a higher risk of death from cervical cancer in
a younger cohort. This population-based cancer regis-
try study covered 9 million people in a single geo-
graphic area in Japan.28 If the aggressiveness and
presence of cervical cancer in a young woman is due
to a genetic alteration, we would expect that would
most likely be seen in regional studies such as the
Japanese study compared with the genetically diverse
population in the United States. There does appear to
be an association of cervical cancer with a large
variety of polymorphisms in a wide variety of genes,
including genes that regulate immunity and
susceptibility,29 cytokine production,30,31 angiogene-
sis, tumor suppressor pathways,32,33 and signal trans-
ducer and activator of transcription pathways.34
Investigations are ongoing to identify genetic
alterations that may make women less likely to clear
persistent HPV infections and more susceptible to the
development of cervical cancer.
This study did not include a comparison group
because it was our primary intention to determine
whether degree of youth was clinically affected.
Lymphovascular space invasion (LVSI) status was
unknown for 50% of the young women and for
425% of the very young women. Of the results
available, 3 of 15 (20%) of very young women and
22 of 97 (23%) of the young women had positive
LVSI. Complete data about LVSI may have led to a
different interpretation of our results. Information
about insurance coverage, income, and social issues
related to care compliance was not collected, and this
may influence the results seen in these young women.
Omission of details of treatment such as time to
completion of therapy for those treated withVolume 38 Number 3
E. Pelkofski et al.chemoradiation and analysis not according to treat-
ment modality are other weaknesses. All 3 cases
eligible for treatment with chemosensitization diag-
nosed before the 1999 National Cancer Institute alert
had received cisplatin. In addition, we recognize that
this study is limited by the small numbers of cases, and
additional multi-institutional studies may clarify these
findings. Nonetheless, our findings offer further
hypothesis-generating data and serve to emphasize
the importance of considering disease distribution,
tumor histology, and grade when determining prog-
nosis in young patients.ACKNOWLEDGMENTS
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